Malvern Panalytical and Concept Life Sciences Launch Amplify Analytics
The partnership combines Malvern’s physicochemical characterization expertise and Concept Life Sciences’ chemistry and analytical services to provide services that focus on analytics, know-how, instrumentation, and expert support to customers.
Malvern Panalytical, a scientific instrumentation provider located in Malvern, United Kingdom, and Concept Life Sciences, a contract research organization based in Cheshire, United Kingdom, announced the launch of Amplify Analytics, a new range of services designed to help pharmaceutical companies identify drug candidates that meet bioavailability and processability requirements, on June 25, 2020.
The partnership combines Malvern’s physicochemical characterization expertise and Concept Life Sciences’ chemistry and analytical services to provide services that focus on analytics, know-how, instrumentation, and expert support to customers, a Malvern press release said. The service will offer specific analytical capabilities and will work to provide third-party management of entire projects, through to deploying techniques, training, and data interpretation support.
“Amplify Analytics combines Concept Life Sciences’ expertise in discovery chemistry, API screening, and GMP manufacturing with Malvern Panalytical’s long-held knowledge and experience in applying physicochemical analysis to drug development,” said Dr. Paul Kippax, Pharmaceutical and Food Sector director at Malvern Panalytical, in the press release. “Within the pharmaceutical industry, an increased emphasis on return on investment and the application of continuous and additive manufacturing methods is pushing the desire to find small molecule drug candidates which easily fit development and scale-up capabilities-this can be unlocked and enabled by the application of physicochemical screening during early development.”
Source: Malvern
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
